HBR

Pomerantz Law Firm Announces the Filing of a Class Action Against Spero Therapeutics, Inc. and Certain Officers – SPRO

Retrieved on: 
Monday, July 18, 2022
News, District court, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MDR, Person, SEC Rule 10b-5, LLP, Review, Lists of action films, GLOBE, Securities Exchange Act of 1934, Food, Urinary tract infection, Lists of schools in England, Tebipenem, Complicated, LCM, New Drug Application, HBR, Complaint, Ext, NASDAQ, Infection, Company, NDA, Court, Degenerative disease, Pomerantz, FDA, Treatment, Workforce, Population, Pharmaceutical industry, Renewable energy, Spero, Pyelonephritis

NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO) and certain of its officers.

Key Points: 
  • NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CareDx, Spero, LMP, and Dentsply Sirona and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, July 16, 2022
News, Audit committee, LMP, Spero, Review, Board, Kidney, Company, Government, California superior courts, Population, Medicare, SEC, Dentsply Sirona, Relevant, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Annual report, Food, Income, Complaint, NASDAQ, Physician, Anesthetic, Defendant, Patient, Class Action, Urinary tract infection, Lists of schools in England, Tebipenem, CDNA, Superior, Degenerative disease, COVID-19, XRAY, NDA, Risk, Growth, Plaque, Workforce, Justice, Mission statement, GLOBE, Complicated, New Drug Application, Marketing, Documentation, Infection, Sale, FDA, ASP, Treatment, HBR, Pharmaceutical industry, Animal, Renewable energy, Audit, Medical device, Property management, P.C, Pyelonephritis

Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.

Key Points: 
  • Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.
  • In order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the Class Period.
  • For more information on the Dentsply Sirona class action go to: https://bespc.com/cases/XRAY
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)

Retrieved on: 
Wednesday, July 13, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, New Drug Application, GPM, Lists of schools in England, HBR, News, Therapy, Company, Review, Food, GLOBE, Urinary tract infection, Time, Suite, Defendant, FDA, NDA, Tebipenem, Court, Workforce, NASDAQ, Medical device, Pharmaceutical industry, Spero

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CareDx, Spero, LMP, and Dentsply Sirona and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, July 11, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HBR, Defendant, Treatment, Superior, Mission statement, Review, New Drug Application, GLOBE, Degenerative disease, Medicare, Lists of schools in England, Spero, Plaque, News, Population, NDA, Class Action, LMP, Tebipenem, Marketing, Government, Income, Relevant, Patient, SEC, Growth, Complicated, Physician, California superior courts, XRAY, Infection, Annual report, Urinary tract infection, Audit committee, CDNA, Justice, Food, Company, ASP, Dentsply Sirona, Anesthetic, Workforce, Kidney, COVID-19, Risk, Sale, Board, Documentation, NASDAQ, Complaint, Pharmaceutical industry, Animal, Renewable energy, Audit, Medical device, Property management, Pyelonephritis, P.C

Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.

Key Points: 
  • Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.
  • In order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the Class Period.
  • For more information on the Dentsply Sirona class action go to: https://bespc.com/cases/XRAY
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spero Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – SPRO

Retrieved on: 
Saturday, July 9, 2022
Review, FDA, Urinary tract infection, Patient, Securities Exchange Act of 1934, Treatment, Court, Infection, LLP, Workforce, GLOBE, Population, Degenerative disease, Company, District court, Complicated, Tebipenem, Lists of schools in England, Pomerantz, Ext, Food, Person, HBR, Lists of action films, Complaint, New Drug Application, NASDAQ, SEC Rule 10b-5, News, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, Pharmaceutical industry, Renewable energy, Spero, Pyelonephritis

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • On March 31, 2022, Spero issued a press release announcing the Companys fourth quarter and full year 2021 financial results.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)

Retrieved on: 
Wednesday, July 6, 2022
Review, FDA, Defendant, Court, Therapy, Workforce, GLOBE, Company, Suite, Tebipenem, Lists of schools in England, Food, HBR, GPM, Urinary tract infection, New Drug Application, NASDAQ, Time, News, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, Medical device, Pharmaceutical industry, Spero

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CareDx, Spero, LMP, and Dentsply Sirona and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, July 5, 2022
XRAY, Urinary tract infection, Patient, Treatment, GLOBE, Marketing, COVID-19, Growth, Degenerative disease, Company, Complicated, Annual report, CDNA, Food, Mission statement, HBR, Class Action, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, FDA, Population, Tebipenem, Plaque, Dentsply Sirona, SEC, Income, Documentation, Defendant, Workforce, Kidney, New Drug Application, NASDAQ, Board, Medicare, News, ASP, Complaint, Review, California superior courts, Justice, Audit committee, Infection, Sale, Lists of schools in England, Relevant, Risk, LMP, Superior, Spero, Anesthetic, Government, Physician, Pharmaceutical industry, Animal, Renewable energy, Audit, Medical device, Property management, P.C, Pyelonephritis

Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.

Key Points: 
  • Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.
  • In order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the Class Period.
  • For more information on the Dentsply Sirona class action go to: https://bespc.com/cases/XRAY
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spero Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – SPRO

Retrieved on: 
Friday, July 1, 2022
Review, FDA, Urinary tract infection, Patient, Securities Exchange Act of 1934, Treatment, Court, Infection, LLP, Workforce, GLOBE, Population, Degenerative disease, Company, District court, Complicated, Tebipenem, Lists of schools in England, Pomerantz, Ext, Food, Person, HBR, Lists of action films, Complaint, New Drug Application, NASDAQ, SEC Rule 10b-5, News, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, Pharmaceutical industry, Renewable energy, Spero, Pyelonephritis

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • On March 31, 2022, Spero issued a press release announcing the Companys fourth quarter and full year 2021 financial results.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CareDx, Spero, LMP, and Dentsply Sirona and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, June 30, 2022
XRAY, Urinary tract infection, Patient, Treatment, GLOBE, Marketing, COVID-19, Growth, Degenerative disease, Company, Complicated, Annual report, CDNA, Food, Mission statement, HBR, Class Action, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, FDA, Population, Tebipenem, Plaque, Dentsply Sirona, SEC, Income, Documentation, Defendant, Workforce, Kidney, New Drug Application, NASDAQ, Board, Medicare, News, ASP, Complaint, Review, California superior courts, Justice, Audit committee, Infection, Sale, Lists of schools in England, Relevant, Risk, LMP, Superior, Spero, Anesthetic, Government, Physician, Pharmaceutical industry, Animal, Renewable energy, Audit, Medical device, Property management, P.C, Pyelonephritis

Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.

Key Points: 
  • Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.
  • In order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the Class Period.
  • For more information on the Dentsply Sirona class action go to: https://bespc.com/cases/XRAY
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Showa Denko Concludes MOU with SK Inc. to Give Consideration to a Plan to Cooperatively Produce High-Purity Gases for Semiconductors in North America

Retrieved on: 
Wednesday, June 29, 2022
Semiconductor, Silicon, ABM, Movement, Transport, Electronics, Carbon, Privacy and the US government, Industry, Government, Growth, Company, HD, SK, ADR, Korea, Light-emitting diode, HBR, Petrochemical, SDK, South Korea, Chemical substance, Computer, Inorganic compound, Aluminium, MOU, CH3F, Congestion

(SDK) (TOKYO: 4004) and SK Incorporated concluded a memorandum of understanding (MOU) to give consideration to a plan to start cooperative work to produce high-purity gases, which are used in semiconductor production processes, in North America.

Key Points: 
  • (SDK) (TOKYO: 4004) and SK Incorporated concluded a memorandum of understanding (MOU) to give consideration to a plan to start cooperative work to produce high-purity gases, which are used in semiconductor production processes, in North America.
  • Supply-demand balance of high-purity gases for wiring process (front-end of semiconductor production process) in the US has been tightening.
  • Therefore, many semiconductor manufacturers in the US want to secure stable supply of high-purity gases for semiconductors.
  • To cope with these problems, SDK and SK Materials, which is an in-house independent company of SK Incorporated and produces high-purity gases for semiconductors, will start to give consideration to a plan to cooperatively produce high-purity gases for semiconductors in North America.